NCT03158974: An overdue trial by ViroXis Corporation
This trial is overdue. It was due to report 5 years, 7 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
Full entry on ClinicalTrials.gov | NCT03158974 |
---|---|
Title | A Phase 2, Open-label, Safety, Tolerability, and Efficacy Trial of a Botanical Drug at One Dose Level for the Treatment of External Condylomata Acuminata (Genital Warts) in Adult Immunocompetent Subjects |
Results Status | Overdue |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | Aug. 1, 2017 |
Completion date | June 17, 2018 |
Required reporting date | June 17, 2019, midnight |
Actual reporting date | None |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | 1698 |